TELA Bio, Inc.

Canaccord Genuity Acts as Financial Advisor to TELA Bio, Inc. on its Successful $70 Million Recapitalization

Canaccord Genuity is pleased to announce that on November 13, 2025, TELA Bio, Inc. (NASDAQ: TELA) (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, closed on a credit facility for up to $70.0 million from Perceptive Advisors, LLC (“Perceptive”). The credit facility consists of an initial loan of $60.0 million received at closing and an additional $10.0 million that can be drawn at the Company’s option by April 30, 2027, upon satisfaction of certain conditions.

Canaccord Genuity acted as financial advisor to TELA Bio in connection with the transaction.

TELA Bio designs, develops and markets innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. The Company’s OviTex and OviTex PRS Reinforced Tissue Matrix products are designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

Founded in 1999, Perceptive Advisors is a leading healthcare focused investment firm with approximately $8 billion of regulatory assets under management. Since inception, Perceptive Advisors has focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward technologies in modern healthcare